Meridian Bioscience Inc 's ability to collect accounts receivable sequentially worsen to 6.25, indicating more challenging environment then in the fourth quarter 2022, but still, it is a far cry from any concerns. Meridian Bioscience Inc 's Accounts Receivable average collection period in the Dec 31 2022 quarter, has increased to 58 days, from 54 days, in the Sep 30 2022 quarter.

If we take a look into Healthcare sector 181 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1450, from overall ranking in the fourth quarter 2022 at 2090.

What is Receivable Turnover Ratio?
What is Meridian Bioscience Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VIVO Receivables Turnover Ratio	(Dec 31 2022) I. Quarter	(Sep 30 2022) IV. Quarter	(Jun 30 2022) III. Quarter	(Mar 31 2022) II. Quarter	(Dec 31 2021) I. Quarter
Y / Y Receivable Change	-6.16 %	-11.82 %	6.28 %	31.9 %	8.22 %
Y / Y Revenue Change	-35.59 %	-13.82 %	6.71 %	30.45 %	-4.92 %
Receivable Turnover Ratio (TTM)	6.25	6.81	6.8	6.81	6.77
VIVO's Total Ranking	# 1450	# 2090	# 1990	# 2236	# 427
Accounts Receivable average collection period days	58	54	54	54	54
Seq. Receivable Change	-11.99 %	5.17 %	-24.16 %	33.67 %	-17.3 %
Seq. Revenue Change	-13.36 %	-3.09 %	-39.07 %	25.91 %	15.93 %

Receivable Turnover Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 4
Healthcare Sector	# 182
Overall Market	# 1450

Receivable Turnover Ratio Statistics
High	Average	Low
1.1	0.84	0.63
(Dec 31 2013)		(Mar 31 2020)

VIVO Company Profile • Back to VIVO Efficiency Comparisons • Compare VIVO Receivables Turnover Ratio to its Competitors

Financial Statements
Meridian Bioscience Inc 's Accounts Receivable	$ 42 Millions	Visit VIVO's Balance sheet
Meridian Bioscience Inc 's Sales TTM	$ 302 Millions	Visit VIVO's Income Statement
Sources of VIVO's Revenues		Visit VIVO's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
VIVO's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
VIVO's Growth Rates	VIVO's Roa	VIVO's Inventory Turnover Ratio	VIVO's Dividend Comparisons
VIVO's Profitability Ratios	VIVO's Roi	VIVO's Asset Turnover Ratio	VIVO's Dividend Growth
VIVO's Valuation Ratios	VIVO's Roe	VIVO's Financial Strength Ratios	VIVO's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2022, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2022	Receivable at quarter ending Dec 31 2022
Aesthetic Medical International Holdings Group Limited	19.68	$ 99.509 Millions	$ 5.056 Millions
Cv Sciences Inc	19.40	$ 16.205 Millions	$ 0.836 Millions
Immunogen inc	19.36	$ 108.782 Millions	$ 5.620 Millions
Thorne Healthtech Inc	19.32	$ 228.731 Millions	$ 11.842 Millions
C4 Therapeutics Inc	19.31	$ 31.096 Millions	$ 1.611 Millions
Sangamo Therapeutics Inc	19.27	$ 111.299 Millions	$ 5.776 Millions
Silence Therapeutics Plc	19.13	$ 17.501 Millions	$ 0.915 Millions
Nutriband Inc	18.94	$ 2.080 Millions	$ 0.110 Millions
Valion Bio Inc	18.78	$ 1.840 Millions	$ 0.098 Millions
Crispr Therapeutics Ag	18.57	$ 1.198 Millions	$ 0.065 Millions
Emmaus Life Sciences Inc	18.21	$ 18.390 Millions	$ 1.010 Millions
U S Physical Therapy Inc	17.92	$ 326.975 Millions	$ 18.243 Millions
Arvinas Inc	17.76	$ 131.400 Millions	$ 7.400 Millions
Biomerica Inc	17.32	$ 16.082 Millions	$ 0.929 Millions
Zomedica Corp	17.15	$ 18.930 Millions	$ 1.104 Millions
Eton Pharmaceuticals Inc	17.07	$ 21.251 Millions	$ 1.245 Millions
Intellia Therapeutics Inc	16.75	$ 52.121 Millions	$ 3.112 Millions
Innovage Holding Corp	16.71	$ 688.894 Millions	$ 41.234 Millions
Chemed Corporation	16.58	$ 2,134.963 Millions	$ 128.736 Millions
Voyager Therapeutics Inc	16.36	$ 40.907 Millions	$ 2.500 Millions
U s Stem Cell Inc	16.32	$ 0.082 Millions	$ 0.005 Millions
Centogene N v	16.31	$ 53.170 Millions	$ 3.260 Millions
Wearable Health Solutions, Inc.	16.29	$ 0.853 Millions	$ 0.052 Millions
Hcw Biologics Inc	16.07	$ 6.722 Millions	$ 0.418 Millions
Revance Therapeutics Inc	16.00	$ 132.565 Millions	$ 8.283 Millions
Mdxhealth Sa	15.92	$ 37.054 Millions	$ 2.327 Millions
Qhslab Inc	15.84	$ 1.243 Millions	$ 0.078 Millions
Strata Critical Medical Inc	15.45	$ 146.120 Millions	$ 9.460 Millions
Ethema Health Corporation	15.39	$ 4.821 Millions	$ 0.313 Millions
Patterson Companies Inc	15.08	$ 6,389.091 Millions	$ 423.718 Millions

Date modified: 2026-08-29T17:15:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.